Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
Launched by HULL UNIVERSITY TEACHING HOSPITALS NHS TRUST · Aug 5, 2010
Trial Information
Current as of June 19, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male/females aged between 40-80 years
- • Previous diagnosis of COPD
- • Acute exacerbation of COPD requiring treatment with antibiotics and/or corticosteroids
- • Symptoms of increased breathlessness, cough, sputum volume or sputum purulence
- • Acute exacerbation of COPD hospitalised within 24hrs of study participation.
- • On a stable therapeutic regimen for COPD for 8 weeks prior to inclusion
- • Known history of cigarette smoking at least 10 pack yrs
- • Willing and able to comply with study procedures
- • Able to provide written informed consent to participate
- Exclusion Criteria:
- • Acute exacerbation of COPD within 8 weeks prior to inclusion
- • Arterial blood gas on admission \< pH 7.26
- • Currently on treatment with mucolytics
- • Patients suffering from post nasal drip, or gastro-oesophageal reflux disease
- • Clinically significant or unstable concurrent disease e.g. left ventricular failure, diabetes mellitus
- • On long-term oxygen therapy
- • Known or suspected hypersensitivity to erdosteine
About Hull University Teaching Hospitals Nhs Trust
Hull University Teaching Hospitals NHS Trust is a leading healthcare organization dedicated to delivering high-quality patient care, education, and research. Located in Hull, England, the Trust encompasses a range of hospitals and healthcare services, providing a comprehensive spectrum of clinical specialties. With a strong commitment to advancing medical science, the Trust actively sponsors and conducts clinical trials that aim to improve patient outcomes and contribute to evidence-based practice. By collaborating with academic partners and leveraging its state-of-the-art facilities, Hull University Teaching Hospitals NHS Trust fosters an innovative research environment that prioritizes patient safety and ethical standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cottingham, East Yorkshire, United Kingdom
Patients applied
Trial Officials
Alyn H Morice, FRCP
Principal Investigator
Hull and east Yorkshire NHS trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials